L

Labiana Health SA
MAD:LAB

Watchlist Manager
Labiana Health SA
MAD:LAB
Watchlist
Price: 2.84 EUR
Market Cap: 20.5m EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one LAB stock under the Base Case scenario is 25.97 EUR. Compared to the current market price of 2.84 EUR, Labiana Health SA is Undervalued by 89%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

LAB Relative Value
Base Case
25.97 EUR
Undervaluation 89%
Relative Value
Price
L
Worst Case
Base Case
Best Case

Valuation Multiples

0.3
P/S
P/S
Price to Sales
0.3
vs History
16
vs Industry
87
Median 3Y
0
Median 5Y
0
Industry
2.4
Forward
0.3
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
20.5
Forward
18.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
47
Median 3Y
0
Median 5Y
0
Industry
15.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
22.8
More Details
4.3
P/B
P/B
Price to Book Value
4.3
vs History
16
vs Industry
16
Median 3Y
2.8
Median 5Y
2.8
Industry
1.9
More Details
0.3
EV/S
EV/S
Enterprise Value to Sales
0.3
vs History
27
vs Industry
89
Median 3Y
0
Median 5Y
0
Industry
2.5
Forward
0.3
More Details
0.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
0.5
vs History
27
vs Industry
87
Median 3Y
0
Median 5Y
0
Industry
4.9
More Details
2.1
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
2.1
vs History
33
vs Industry
51
Median 3Y
0
Median 5Y
0
Industry
12.4
Forward
2.1
More Details
4.5
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
4.5
vs History
16
vs Industry
46
Median 3Y
0
Median 5Y
0
Industry
15.5
Forward
3.2
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
42
Median 3Y
0
Median 5Y
0
Industry
14
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
17.9
More Details
0.5
EV/IC
EV/IC
Enterprise Value to IC
0.5
vs History
61
vs Industry
74
Median 3Y
0.5
Median 5Y
0.5
Industry
1.8
More Details

Multiples Across Competitors

LAB Competitors Multiples
Labiana Health SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
ES
Labiana Health SA
MAD:LAB
20m EUR 0.3 -17 2.1 4.5
US
Eli Lilly and Co
NYSE:LLY
714.2B USD 15.9 67.4 39.3 43.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
363.4B USD 4.1 25.8 12.1 15.9
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.5 18.8 12.4 14.1
CH
Roche Holding AG
SIX:ROG
196B CHF 3.3 17.1 9.6 11.4
US
Merck & Co Inc
NYSE:MRK
207.4B USD 3.2 12.1 8.2 9.7
CH
Novartis AG
SIX:NOVN
174.8B CHF 3.9 17.1 10.4 13.3
UK
AstraZeneca PLC
LSE:AZN
158.6B GBP 3.8 28.9 125.6 191.8
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
US
Pfizer Inc
NYSE:PFE
127.4B USD 2 15.9 7.9 11.2
P/E Multiple
Earnings Growth PEG
ES
L
Labiana Health SA
MAD:LAB
Average P/E: 25.4
Negative Multiple: -17 		N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67.4
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
25.8
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.8
19%
1
CH
Roche Holding AG
SIX:ROG
17.1
16%
1.1
US
Merck & Co Inc
NYSE:MRK
12.1
18%
0.7
CH
Novartis AG
SIX:NOVN
17.1
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.9
36%
0.8
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.9
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ES
L
Labiana Health SA
MAD:LAB
Average EV/EBITDA: 394
2.1
56%
0
US
Eli Lilly and Co
NYSE:LLY
39.3
30%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.1
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
12.4
15%
0.8
CH
Roche Holding AG
SIX:ROG
9.6
8%
1.2
US
Merck & Co Inc
NYSE:MRK
8.2
9%
0.9
CH
Novartis AG
SIX:NOVN
10.4
5%
2.1
UK
AstraZeneca PLC
LSE:AZN
125.6
9%
14
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.9
3%
2.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ES
L
Labiana Health SA
MAD:LAB
Average EV/EBIT: 1 697.1
4.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.4
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.9
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.1
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.4
9%
1.3
US
Merck & Co Inc
NYSE:MRK
9.7
12%
0.8
CH
Novartis AG
SIX:NOVN
13.3
8%
1.7
UK
AstraZeneca PLC
LSE:AZN
191.8
21%
9.1
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
11.2
10%
1.1

See Also

Summary
LAB intrinsic value, competitors valuation, and company profile.
DCF Valuation
LAB stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LAB stock valuation using valuation multiples.
Wall Street Estimates
LAB price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LAB stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 245,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.